20:33 , Feb 5, 2019 |  BC Extra  |  Company News

FDA psychiatry product division director joins Allergan

Following a 12-year tenure as director of FDA’s Division of Psychiatry Products, Mitchell Mathis has joined Allergan plc (NYSE:AGN) as CMO for CNS products. Mathis left FDA on Jan. 19 and joined Allergan later in...
19:52 , Feb 1, 2019 |  BC Week In Review  |  Financial News

Drug delivery company Lyndra raises $55M series B

Lyndra Therapeutics Inc. (Watertown, Mass.) raised $55 million in a series B round to advance compounds delivered via its capsule platform. Polaris Partners led the round and was joined by all other original investors and...
12:04 , Jan 29, 2019 |  BC Extra  |  Financial News

Drug delivery company Lyndra raises $55M series B

Lyndra Therapeutics Inc. (Watertown, Mass.) raised $55 million in a series B round to advance compounds delivered via its capsule platform. Polaris Partners led the round and was joined by all other original investors and...
18:43 , Jan 18, 2019 |  BC Week In Review  |  Clinical News

Aptinyx's pain compound misses Phase II endpoint

Aptinyx Inc. (NASDAQ:APTX) said all three doses of NYX-2925 missed the primary endpoint in a Phase II trial to treat pain associated with diabetic peripheral neuropathy. The primary endpoint measured mean change in average daily...
18:36 , Jan 16, 2019 |  BC Extra  |  Clinical News

Aptinyx tumbles after pain compound misses Phase II endpoint

Aptinyx Inc. (NASDAQ:APTX) lost $11.85 (66%) to $5.98 Wednesday after it said all three doses of NYX-2925 missed the primary endpoint in a Phase II trial to treat pain associated with diabetic peripheral neuropathy. The...
17:47 , Jan 11, 2019 |  BC Week In Review  |  Clinical News

Axsome's AXS-05 meets in Phase II for MDD

Axsome Therapeutics Inc. (NASDAQ:AXSM) added $4.24 (161%) to $6.87 on Jan. 7 after reporting that AXS-05 met the primary endpoint in the Phase II ASCEND trial to treat moderate-to-severe major depressive disorder (MDD). On the...
17:27 , Jan 11, 2019 |  BC Week In Review  |  Clinical News

NeuroRx's NRX-101 improves depression and suicidality in Phase II

NeuroRx Inc. (Wilmington, Del.) said NRX-101 improved depression and suicidality in the Phase II STABIL-B trial to treat severe bipolar depression and acute suicidal ideation and behavior. Data were presented in December at the American...
22:10 , Jan 7, 2019 |  BC Extra  |  Clinical News

Sage rebounds after next-gen postpartum depression readout

Sage Therapeutics Inc. (NASDAQ:SAGE) gained $41.62 (43%) to $139.13 on Monday after it said SAGE-217 met the primary endpoint in the Phase III ROBIN trial to treat women with severe postpartum depression. The move translates...
15:55 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Neurology company Cadent emerges with $40M series B

Cadent Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with news of a $40 million tranched series B round to bring its lead compound through Phase II trials to treat essential tremor and spinocerebellar ataxia (SCA)....
11:00 , Nov 15, 2018 |  BC Extra  |  Financial News

Neurology company Cadent emerges with $40M series B

Cadent Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with news of a $40 million tranched series B round to bring its lead compound through Phase II trials to treat essential tremor and spinocerebellar ataxia (SCA)....